Andrew Alliance, which is based in Switzerland and will be opening an office in Boston, is a developer of life science robotics. In January 2013, Andrew Alliance introduced Andrew, a co-worker robot designed to assist scientists by taking over the manipulation of commercial laboratory pipettes.
Funding for the round came from Omega Funds, which specializes in late-stage life science investments.
Andrew Alliance indicated the funding would go toward expanding the reach of its robots through new developments and the establishment of commercial operations in the U.S. market.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
